Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 5147468, 10 pages
http://dx.doi.org/10.1155/2016/5147468
Review Article

Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Nephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700503 Iasi, Romania

Received 24 February 2016; Accepted 27 March 2016

Academic Editor: Konstantinos Papatheodorou

Copyright © 2016 Luminita Voroneanu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.idf.org.
  2. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
  3. http://www.euro.who.int.
  4. American Diabetes Association, “Economic costs of diabetes in the U.S. in 2012,” Diabetes Care, vol. 36, no. 4, pp. 1033–1046, 2013. View at Publisher · View at Google Scholar
  5. K. Flora, M. Hahn, H. Rosen, K. Benner, and K. Benner, “Milk thistle (Silybum marianum) for the therapy of liver disease,” The American Journal of Gastroenterology, vol. 93, pp. 139–143, 1998. View at Google Scholar
  6. N.-C. Kim, T. N. Graf, C. M. Sparacino, M. C. Wani, and M. E. Wall, “Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum),” Organic and Biomolecular Chemistry, vol. 1, no. 10, pp. 1684–1689, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Wellington and B. J. Adis, “Silymarin: a review of its clinical properties in the management of hepatic disorders,” BioDrugs, vol. 15, no. 7, pp. 465–489, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Bosisio, C. Benelli, and O. Pirola, “Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes,” Pharmacological Research, vol. 25, no. 2, pp. 147–165, 1992. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Tasduq, K. Peerzada, S. Koul, R. Bhat, and R. K. Johri, “Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin,” Hepatology Research, vol. 31, no. 3, pp. 132–135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. V. Kiruthiga, R. B. Shafreen, S. K. Pandian, and K. P. Devi, “Silymarin protection against major reactive oxygen species released by environmental toxins: exogenous H2O2 exposure in erythrocytes,” Basic & Clinical Pharmacology & Toxicology, vol. 100, no. 6, pp. 414–419, 2007. View at Publisher · View at Google Scholar
  11. P. V. Kiruthiga, S. K. Pandian, and K. P. Devi, “Silymarin protects PBMC against B(a)P induced toxicity by replenishing redox status and modulating glutathione metabolizing enzymes—an in vitro study,” Toxicology and Applied Pharmacology, vol. 247, no. 2, pp. 116–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. O. Abdel-Zaher, R. H. Abdel-Hady, M. M. Mahmoud, and M. M. Y. Farrag, “The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage,” Toxicology, vol. 243, no. 3, pp. 261–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Al-Jassabi, A. Saad, M. S. Azirun, and A. Al-Omari, “The role of Silymarin in prevention of Alloxan-induced diabetes mellitus in Balb/C mice,” American-Eurasian Journal of Toxicological Sciences, vol. 3, no. 3, pp. 172–176, 2011. View at Google Scholar
  14. K. Khazim, Y. Gorin, R. C. Cavaglieri, H. E. Abboud, and P. Fanti, “The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo,” American Journal of Physiology—Renal Physiology, vol. 305, no. 5, pp. F691–F700, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Turgut, O. Bayrak, F. Catal et al., “Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats,” International Urology and Nephrology, vol. 40, no. 2, pp. 453–460, 2008. View at Publisher · View at Google Scholar
  16. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Malihi, A. Hosseini-Tabatabaei, H. Esmaily, R. Khorasani, M. Baeeri, and M. Abdollahi, “Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus,” Central European Journal of Biology, vol. 4, no. 3, pp. 369–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. Navarro-González, C. Mora-Fernández, M. M. De Fuentes, and J. García-Pérez, “Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy,” Nature Reviews Nephrology, vol. 7, no. 6, pp. 327–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. K. Fallahzadeh, B. Dormanesh, M. M. Sagheb et al., “Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial,” American Journal of Kidney Diseases, vol. 60, no. 6, pp. 896–903, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-D. Jia, M. Bauer, J. J. Cho et al., “Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1(I) and TIMP-1,” Journal of Hepatology, vol. 35, no. 3, pp. 392–398, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. J. P. Liu, M. Zhang, W. Y. Wang, and S. Grimsgaard, “Chinese herbal medicines for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD003642, 2004. View at Google Scholar · View at Scopus
  22. D.-H. Jeong, G.-P. Lee, W.-I. Jeong et al., “Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl4-induced hepatic fibrosis,” World Journal of Gastroenterology, vol. 11, no. 8, pp. 1141–1148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Clichici, D. Olteanu, A.-L. Nagy, A. Oros, A. Filip, and P. A. Mircea, “Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl4-treated rats,” Journal of Medicinal Food, vol. 18, no. 3, pp. 290–298, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. R. E. Gilbert, A. Akdeniz, T. J. Allen, and G. Jerums, “Urinary transforming growth factor-β in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology,” Nephrology Dialysis Transplantation, vol. 16, no. 12, pp. 2442–2443, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. B. P. Jacobs, C. Dennehy, G. Ramirez, J. Sapp, and V. A. Lawrence, “Milk thistle for the treatment of liver disease: a systematic review and meta-analysis,” The American Journal of Medicine, vol. 113, no. 6, pp. 506–515, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Velussi, A. M. Cernigoi, D. M. Ariella, F. Dapas, C. Caffau, and M. Zilli, “Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients,” Journal of Hepatology, vol. 26, no. 4, pp. 871–879, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Suksomboon, N. Poolsup, S. Boonkaew, and C. C. Suthisisang, “Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes,” Journal of Ethnopharmacology, vol. 137, no. 3, pp. 1328–1333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. H. F. Huseini, B. Larijani, R. Heshmat et al., “The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial,” Phytotherapy Research, vol. 20, no. 12, pp. 1036–1039, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. A.-R. Hussain, “Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes,” Journal of Medicinal Food, vol. 10, no. 3, pp. 543–547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Ebrahimpour Koujan, B. P. Gargari, M. Mobasseri, H. Valizadeh, and M. Asghari-Jafarabadi, “Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial,” Phytomedicine, vol. 22, no. 2, pp. 290–296, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Mannucci, I. Dicembrini, A. Lauria, and P. Pozzilli, “Is glucose control important for prevention of cardiovascular disease in diabetes?” Diabetes Care, vol. 36, supplement 2, pp. S259–S263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. H. C. Gerstein, M. E. Miller, R. P. Byington et al., “Effects of intensive glucose lowering in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar
  33. V. Papademetriou, L. Lovato, M. Doumas et al., “Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes,” Kidney International, vol. 87, no. 3, pp. 649–659, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Hemmingsen, S. S. Lund, C. Gluud et al., “Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials,” British Medical Journal, vol. 343, Article ID d6898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Baigent, A. Keech, P. M. Kearney et al., “Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins,” The Lancet, vol. 366, no. 9493, pp. 1267–1268, 2005. View at Publisher · View at Google Scholar
  36. B. Mihaylova, J. Emberson, L. Blackwell et al., “The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials,” The Lancet, vol. 380, no. 9841, pp. 581–590, 2012. View at Publisher · View at Google Scholar
  37. P. M. Kearney, L. Blackwell, R. Collins et al., “Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis,” The Lancet, vol. 371, no. 9607, pp. 117–112, 2008. View at Publisher · View at Google Scholar
  38. M. Strazzabosco, “Effects of silybinin on biliary lipid composition,” Journal of Hepatology, vol. 12, pp. 290–292, 1999. View at Google Scholar
  39. C. Vaughu, A. M. Jr. Gotto, and C. T. Basson, “The evolving role of silymarin in management of atherosclerosis,” Journal of the American College of Cardiology, vol. 36, no. 1, pp. 1–5, 2006. View at Google Scholar
  40. F. Lirussi, A. Beccarello, G. Zanette et al., “Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent,” Diabetes, Nutrition & Metabolism, vol. 15, no. 4, pp. 222–231, 2002. View at Google Scholar
  41. H. M. Alkuraishy and S. Alwindy, “Beneficial effects of silymarin on lipid profile in hyperlipidemic patients: placebo controlled clinical trail,” Webmed Central Pharmacology, vol. 3, no. 2, Article ID WMC002966, 2012. View at Publisher · View at Google Scholar
  42. H. J. Suh, S. Y. Cho, E. Y. Kim, and H. S. Choi, “Blockade of lipid accumulation by silibinin in adipocytes and zebrafish,” Chemico-Biological Interactions, vol. 227, pp. 53–62, 2015. View at Publisher · View at Google Scholar